Busulfan + cyclophosphamide + etoposide

Busulfan + cyclophosphamide + etoposide (often abbreviated as BuCyE) is a combination chemotherapy regimen primarily used as a conditioning treatment before autologous stem cell transplantation (ASCT), especially in patients with hematologic malignancies such as Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, and multiple myeloma[1][2][7]. Each component is an alkylating or cytotoxic agent: - Busulfan is an alkylating agent that causes DNA cross-linking and inhibits DNA replication. - Cyclophosphamide is also an alkylating agent that must be activated in the liver; it works by slowing or stopping the growth of cancer cells[3][5]. - Etoposide inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. The combination aims to maximize anti-tumor efficacy while preparing the bone marrow for transplantation. The regimen has been shown to be effective and relatively well tolerated but can cause significant toxicities such as mucositis and hepatic veno-occlusive disease[1][2][7].

Other names

BuCyE